Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

We'll have to wait a couple of weeks for the presentations but, given the OS trend, I believe the SUCCEED trial will meet its secondary endpoint as well.

The aml abstract confirmed that ponatinib is just as effective in aml as the current frontline treatments are in cml.

Posts on this board to the contrary, I found the endometrial results superior to those achieved in the everolimus trial (although the AE's in the separate endometrial trial show the current dose may not be tolerable in a very sick and elderly patient group).

All that said, however, it wouldn't surprise me if the stock initially trades off this morning. Apparently there are a lot of folks who just aren't willing to wait for the actually data needed to make an INFORMED decision.